- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06944704
Evaluation of Efficacy, Safety and Molecular Mechanism of Pentoxifylline Supplementation in Patients With Hepatic and Obstructive Jaundice
Clinical Study Evaluating Efficacy, Safety and Molecular Mechanism of Pentoxifylline Supplementation in Patients With Hepatic and Post Hepatic Jaundice
Investigating the efficacy, safety, and molecular mechanism of Pentoxifylline supplementation in improving elevated direct bilirubin level and liver function tests in patients with hepatic and post-hepatic jaundice
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Tanta, Egypt, 31111
- Faculty of Pharmacy, Tanta University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients age 18-70 years old.
- Patients diagnosed with jaundice and increased level direct bilirubin ≥ 3 mg/dL.
Exclusion Criteria:
-
Pregnancy.
- Nursing mothers.
- Patients with increased indirect bilirubin level.
- Patients who have Gilbert syndrome or Crigler Najjar syndrome.
- History of intolerance and hypersensitivity to Pentoxifylline or to xanthine derivatives such as caffeine, theophylline.
- Recent hemorrhage.
- Patients who have risk factors potentially complicated by hemorrhage.
- Taking anticoagulants or antiplatelet therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control arm
20 patients who will receive supportive treatment for jaundice only, for 3 months. |
|
|
Experimental: PTX arm
20 patients who will receive oral Pentoxifylline 400 mg twice daily in addition to supportive treatment, for 3 months. |
Patients will receive oral Pentoxifylline 400 mg twice daily in addition to supportive treatment, for 3 months. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The change from baseline in (Total and Direct bilirubin)
Time Frame: The participants will be assessed before initiation of the study (baseline), and at the end of the study up to12 weeks.
|
measurement of(Total and Direct bilirubin) in mg/dL from blood samples will be assessed for all participants. |
The participants will be assessed before initiation of the study (baseline), and at the end of the study up to12 weeks.
|
|
The change from baseline in aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase (ALP)
Time Frame: The participants will be assessed before initiation of the study (baseline), and at the end of the study after 3 months.
|
measurement of aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase (ALP) all in U/L from blood samples will be assessed for all participants. |
The participants will be assessed before initiation of the study (baseline), and at the end of the study after 3 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse events and toxicity
Time Frame: up to 12 weeks
|
Adverse events and toxicity will be graded using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5 |
up to 12 weeks
|
|
Change in total antioxidant capacity (TAC) level,
Time Frame: The participants will be assessed before initiation of the study (baseline), and at the end of the study up to 12 weeks.
|
Assessment of total antioxidant capacity (TAC) level by ELISA Kits according to manufacturer's instructions. |
The participants will be assessed before initiation of the study (baseline), and at the end of the study up to 12 weeks.
|
|
Change in tumor necrosis factor alpha (TNF-α)
Time Frame: The participants will be assessed before initiation of the study (baseline), and at the end of the study up to 12 weeks.
|
Assessment of tumor necrosis factor alpha (TNF-α) level by ELISA Kits according to manufacturer's instructions. |
The participants will be assessed before initiation of the study (baseline), and at the end of the study up to 12 weeks.
|
|
Change in liver-fatty acid binding protein (L-FABP)
Time Frame: The participants will be assessed before initiation of the study (baseline), and at the end of the study up to 12 weeks.
|
Assessment of liver-fatty acid binding protein (L-FABP) level by ELISA Kits according to manufacturer's instructions. |
The participants will be assessed before initiation of the study (baseline), and at the end of the study up to 12 weeks.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Hyperbilirubinemia
- Skin Manifestations
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Digestive System Diseases
- Jaundice
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Purinones
- Purines
- Xanthines
- Theobromine
- Pentoxifylline
Other Study ID Numbers
- TP/RE1/24Ph-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Individual participant data will not be publicly shared to ensure participant privacy and confidentiality, as explicit consent for secondary data sharing was not obtained during the study enrollment.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.